The effectiveness of treatment in patients with prostatitis and erectile dysfunction L-arginine
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
This article discusses the relevance of the use of L-arginine in the treatment of prostatitis and erectile dysfunction (ED). Treatment of patients with ED drugs L-arginine shows good results and finds all wider application. Among the drugs L-arginine for oral use Valargin highlighted a number of advantages. Valargin is used 1–2 times a day, which ensures a high daily dose of L-arginine (3000 mg to 6000 mg per day). Valargin is the drug of L-arginine to stimulate the reproductive system of men and women of different age groups.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Горпинченко И.И., Применение L-аргинина в лечении эректильной дисфункции // Здоровье Мужчины, 2013. – No 1. – С. 14–15.
Горпинченко И.И. Геронтологическая сексопатология. – К.: Здоровье, 1991. – 168 с.
Бабушкина А.В. L-аргинин с точки зрения доказательной медицины // Врачу-практику, No 6 (74). – XI–XII 2009 г.
Neuzillet Y., Hupertan V., Cour F., Botto H. & Lebret T. А randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction Andrology, 2013, 1, 223–228.
Zabkowski T, Peterek J, Stawar B, Bejm J, Sulik M, Bañcer M. The results of treatment of chronic prostatitis on the background of anaerobic bacterial and fungal infections // Wiad Lek. – 1999;52(9–10):456–61.
Shoskes D.A. Use of antibiotics in chronic prostatitis syndromes // The Canadian Journal of Urology, 2001 Jun;8 Suppl 1:24–8.
Lipsky B.A. 1999, Prostatitis and urinary tract infection in men: what’s new; what’s true? American Journal of Medicine 1999 Mar; 106(3):327–34.
Ledda A., Belcaro G., Cesarone M.R., Dugall M., Schönlau F. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study, BJU international, 2010 Oct; 106(7): 1030-3. doi: 10.1111/j.1464(410X.2010.09213.x. Epub 2010 Feb 22.
Lummus W.E., Thompson I. Prostatitis, Emergency medicine clinics of North America, 2001 Aug; 19(3):691–707.
Lee JC, Microbiology of the prostate // Current urology reports, 2000 Aug;1(2):159–63.
Strohmaier WL, Bichler KH., Comparison of symptoms, morphological, microbiological and urodynamic findings in patients with chronic prostatitis/pelvic pain syndrome. Is it possible to differentiate separate categories? // Urologia internationalis, 2000; 65(2):112–6.
Stanislavov R, Nikolova V. Treatment of erectile dysfunction with pycnogenol and Larginine // J Sex Marital Ther . 2003;29(3):207–213.
Best L.G., Nadeau M., Bercier S.Genetic variants, endothelial function, and risk of preeclampsia among american indians / L.G. Best, М. Nadeau, S. Bercier // Hypertens Pregnancy. 2012. 31(1):1–10.
Le Couter J., Moritz D.R., Phillips G.L. et al. Angiogenesis-independent endothelial protection of liver: role of VEGF / J. Le Couter, D.R. Moritz, G.L. Phillips et al. // Science 2003. 299:
–893.
Grøntved A., Andersen L.B., Franks P.W. et al. NOS3 variants, physical activity, and blood pressure in the European Youth Heart Study / А. Grøntved, L.B. Andersen, P.W. Franks et al. // Am J Hypertens. – 2011 Apr; 24(4):444–50.
Hon W.M., Lee W.H., Khoo H.E. Nitric oxide in liver diseases / W.M. Hon, W.H. Lee, Н.Е. Khoo // Annals of the New Jork Academy of sciences. – 2002. 962: 278–295.
Li J., Cun Y., Tang W.R. et al. Association of eNOS gene polymorphisms with essential hypertension in the Han population in southwestern China / J. Li, Y. Cun, W.R. Tang et al. //
Genet Mol Res. – 2011 Sep 27.10(3):2202–12.
Meigs J.B., Rifai N. Biomarkers of endothelial dysfunction / J.B. Meigs, N. Rifai // JAMA 2004. 297:1978–1986.
Möllsten A., Lajer M., Jorsal A., Tarnow L. The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes / А. Möllsten, М. Lajer, А. Jorsal, L. Tarnow // Mol Genet Metab. 2009. May. 97(1):80–4.
Rai H., Fitt J., Sharma A. K. et al. Lack of association between Glu298Asp polymorphism and coronary artery disease in North Indians. / Н. Rai, J. Fitt, А.К. Sharma et al. // Mol Biol Rep. – 2011. Dec 30.
Wynn А. Cellular and molecular mechanisms of fibrosis / А. Wynn // J Pathol. 2008. 2 (14). 199–210.
Алмакаева Л.Г., Е.В. Литвинова. Аргинин и его применение в медицине и фармации // Ліки України, No 1 (5) / 2011, 23–26.
Аргинин в медицинской практике (Обзор литературы) / Степанов Ю.М., Кононов И.Н., Журбина А.И., Филиппова А.Ю. // Сучас. гастроентерологія. – 2005. – No 4. – С. 121–127.
Boger R.H. and Bode-Boger S.M. The clinical pharmacology of L-Arginine // Ann. Rev. Pharmacol. Toxicol. – 2001. – V. 41. – P. 79–99.
Граник В.Г. Метаболизм L-аргинина. // Хим-фарм. журн. – 2003. – No 3. – С. 3–20.
Bode-Bоger S.M. Effect of L-arginine supplementation on NO production in man // European Journal of Clinical Pharmacology. – 2006 – V. 62, Supplement 13 – P. 91–99.
Wu G., Meininger C.J. Arginine nutrition and cardiovascular function // J. Nutr. – 2000. – V. 130 – P. 2626–2629.
Rector T.S., Bank A.J., Mullen K.A., Tschumperlin L.K. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure // Circulation. – 1997.
– V. 18. – P. 1674–1679.
Kelly B.S., et al. Oral arginine improves blood pressure in renal transplant and hemodialysis patients // J. Parenter. Enteral. Nutr. – 2001. – V. 25. – P. 194–202.
Neri I., et al. Effects of acute L-arginine infusion on non-stress test in hypertensive pregnant women // J. Matern. Fetal. Neonatal. Med. – 2004. – V. 16. – P. 23–28.
Palloshi A., et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries // Am. J. Cardiol. – 2004. – V. 93. – P. 933–938.
Созыкин А.В. Ноева Е.А., Балахонова Т.В. и др. Влияние L-аргинина на агрегацию тромбоцитов, функцию эндотелия и толерантность к физической нагрузке у пациентов со стабильной стенокардией напряжения // Тер. архив. – 2000. – No 8. – С. 24–27.
Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine // Lancet. – 1991. – V. 338. – P. 1546–1550.
Регистр лекарственных средств России. Энциклопедия лекарств / Г.Л. Вышковский. – М.: Медицина, 2006, 2005. – 1392 с.
Шугалей В.С., Ананян А.А. Регуляция аргинином активности цитохрома Р450 и перекисного окисления липидов в печени и семенниках крыс при гипоксии // Вопр. мед. хим. – 1991. – No 4. – С. 51–54.
Милютина Н.П., Ананян А.А., Шугалей В.С. Антирадикальный и антиоксидантный эффект аргинина и его влияние на активность перекисного окисления липидов при гипоксии
//Бюл. эксп. биол. и мед. – 1990. – Т. 60, No 3. – С. 263–265.
Аминокислоты и их производные в биологии и медицине: Материалы II междунар. науч. конф., 10–12 окт. 2001 г., Гродно. / Под общ. ред. Л.И. Нефедова. – Гродно: ГрГУ, 2001. – 124 с.
Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study, BJU international, 1999 Feb; 83(3): 269–73.
Хирманов В.Н. Эректильная дисфункция Кардиологические аспекты проблемы // Справочник поликлинического врача, No 5, 2004.
